

A practical guide for providers on helping patients locate and fill Belsomra prescriptions. Includes pharmacy strategies, tools, and alternative options.
Prescribing Belsomra (Suvorexant) is straightforward. Getting your patient's prescription filled is often the harder part. As a brand-only dual orexin receptor antagonist (DORA) with a monthly cash price of $450 to $550, Belsomra presents unique challenges at the dispensing level that can disrupt patient care.
This guide offers practical, actionable strategies for providers to help patients navigate Belsomra availability issues and maintain continuity of treatment.
When you prescribe Belsomra, your patients may encounter one or more of the following barriers at the pharmacy:
Each of these can result in the patient leaving without their medication. Proactive planning can address most of them before they occur.
Not all pharmacies are equal when it comes to stocking brand-name medications. Consider these recommendations:
CVS, Walgreens, Walmart, and Rite Aid are more likely to have Belsomra in stock or to be able to order it quickly. Their centralized distribution systems and higher volume make it easier to maintain stock of brand-name medications.
For patients with stable prescriptions, mail-order through their insurance plan is often the best option. Benefits include:
Common mail-order pharmacies include Express Scripts, CVS Caremark, OptumRx, and Amazon Pharmacy.
Some specialty pharmacies stock DORAs more consistently. If your health system has an outpatient specialty pharmacy, it may be worth checking whether they carry Belsomra.
MedFinder for Providers offers a pharmacy locator tool that helps identify pharmacies with Belsomra availability in real time. Share this with your patients or your staff to streamline the dispensing process.
Insurance hurdles are the most common source of delay. Here's how to stay ahead of them:
Don't wait for the pharmacy to submit a PA request. Include the following in your proactive PA submission:
Most payers require trial of at least one generic alternative before approving Belsomra. Common step therapy agents include:
Document all prior trials thoroughly in the patient's chart to facilitate PA approvals.
If a PA is denied, appeal with additional clinical documentation. Peer-to-peer reviews can be particularly effective for DORA prescriptions when you can articulate why the GABA-ergic alternatives are inappropriate for the specific patient.
Even with insurance, patients may face significant out-of-pocket costs. Have your staff prepare to share these resources:
Commercially insured patients may qualify for the Merck Belsomra Savings Card, which can reduce copays to as low as $0. Available at activatethecard.com/8193. Not valid for government insurance (Medicare, Medicaid, Tricare, VA).
Uninsured or underinsured patients who meet income criteria may receive Belsomra free of charge through Merck Helps. Your office can assist patients with the application process.
For cash-paying patients, discount programs like GoodRx and SingleCare can reduce the price, though savings are modest for brand-name medications compared to generics.
For a comprehensive patient resource on cost reduction, refer patients to our guide: How to save money on Belsomra.
When Belsomra is truly inaccessible, having predefined backup options prevents treatment gaps:
Note: These may have similar availability and payer challenges.
Consider implementing these workflows to reduce the burden on providers and staff:
Set expectations during the prescribing visit:
Proactive communication builds trust and reduces patient frustration.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.